Showing 5261-5270 of 5771 results for "".
- Q Biomed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression From Washington Universityhttps://modernod.com/news/q-biomed-licenses-novel-biomarker-for-monitoring-glaucoma-severity-and-progression-from-washington-university/2476369/Q BioMed has announced it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) from the Washington University in St. Louis. Determining the severity
- Topcon Introduces the IS-100 Ophthalmic Unithttps://modernod.com/news/topcon-introduces-the-is-100-ophthalmic-unit/2476366/Topcon Medical Systems has announced the launch of the new IS-100 Ophthalmic Unit to the export market. The IS-100 will replace the existing IS-600N model which has been discontinued, and includes several new features that simplifies the installation, enhances its durability and facilitates its u
- ProQR Reports First Patient Dosing in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-reports-first-patient-dosing-in-phase-1-2-stellar-trial-of-qr-421a-for-usher-syndrome-type-2/2476365/ProQR Therapeutics announced the first patient dosed in the phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP). Interim data from the study are expected to be announced mid-2019. “There are no effective treat
- Zeiss Receives FDA Clearance for Epithelial Thickness Mapping for CIRRUS HD-OCThttps://modernod.com/news/zeiss-receives-fda-clearance-for-epithelial-thickness-mapping-for-cirrus-hd-oct/2476359/Zeiss announced that it has received FDA 510(k) clearance for the CIRRUS HD-OCT platform, expanding the capabilities of its Anterior Segment Premier Module to include epithelial thickness mapping (ETM). According to refractive specialist John Doane, MD, of Discover Vision Center in Kansas
- 2019 Bressler Prize Awarded to Vladimir Kefalov, PhD, for Outstanding Accomplishments in Vision Science Researchhttps://modernod.com/news/2019-bressler-prize-awarded-to-vladimir-kefalov-phd-for-outstanding-accomplishments-in-vision-science-research/2476357/Lighthouse Guild announced that Vladimir Kefalov, PhD, has been awarded the 2019 Bressler Prize for his outstanding advances in vision science research. Dr. Kefalov is one of the leading retinal scientists in the world. His work has generated new insights into mecha
- FDA Grants Breakthrough Device Designation to Concussion Assessment Devicehttps://modernod.com/news/fda-grants-breakthrough-device-designation-to-concussion-assessment-device/2476351/SyncThink announced that the FDA has granted Breakthrough Device Designation to EYE-SYNC, an objective eye-tracking platform. The EYE-SYNC platform is used to assist clinicians in evaluating visual impairments, monitor recovery, and support the rehabilitation of ocular-motor and ocular-vestibular
- Bausch Health Completes Acquisition of Certain Assets Of Synergy Pharmaceuticalshttps://modernod.com/news/bausch-health-completes-acquisition-of-certain-assets-of-synergy-pharmaceuticals/2476352/Bausch Health Companies announced that the company has completed the acquisition of certain assets of Synergy Pharmaceuticals for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities.
- Biogen to Acquire Gene Therapy Company Nightstar Therapeuticshttps://modernod.com/news/biogen-to-acquire-gene-therapy-company-nightstar-therapeutics-in-800-million-deal/2479586/Biogen announced that it has entered into an agreement to acquire gene therapy company Nightstar Therapeutics for $800 million. London-based Nightstar is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. “Ophthalmology is an emerging growth area for Biogen
- Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophyhttps://modernod.com/news/apellis-resumes-dosing-in-its-phase-3-program-for-patients-with-geographic-atrophy/2479589/Apellis Pharmaceuticals announced that it has resumed enrollment in its two phase 3 GA trials (DERBY & OAKS) with intravitreal APL-2 for the treatment of geographic atrophy (GA). In October 2018, Apellis
- Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticalshttps://modernod.com/news/bausch-health-to-acquire-certain-assets-of-synergy-pharmaceuticals/2476257/Bausch Health Companies announced that the company was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities.